{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:53:32Z","timestamp":1793404412938,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG052510"],"award-info":[{"award-number":["R01AG052510"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41591-025-03569-y","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T21:43:33Z","timestamp":1742939013000},"page":"1586-1591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Escitalopram for agitation in Alzheimer\u2019s dementia: a randomized controlled phase 3 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8324-2560","authenticated-orcid":false,"given":"Tarek K.","family":"Rajji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-860X","authenticated-orcid":false,"given":"Sheriza N.","family":"Baksh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Shade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-3731","authenticated-orcid":false,"given":"Zahinoor","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9888-008X","authenticated-orcid":false,"given":"Amer M.","family":"Burhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid R.","family":"Okhravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad R.","family":"Padala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon S.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-1738","authenticated-orcid":false,"given":"Anton P.","family":"Porsteinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine G.","family":"Lyketsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the S-CitAD Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"3569_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/01.JGP.0000221334.65330.55","volume":"14","author":"CG Lyketsos","year":"2006","unstructured":"Lyketsos, C. G. et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am. J. Geriatr. Psychiatry 14, 561\u2013573 (2006).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"3569_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/gps.5030","volume":"34","author":"R Halpern","year":"2019","unstructured":"Halpern, R. et al. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease\/dementia. Int. J. Geriatr. Psychiatry 34, 420\u2013431 (2019).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"3569_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211953","volume":"14","author":"M Panca","year":"2019","unstructured":"Panca, M. et al. Healthcare resource utilisation and costs of agitation in people with dementia living in care homes in England\u2014the Managing Agitation and Raising QUality of LifE in Dementia (MARQUE) study. PLoS ONE 14, e0211953 (2019).","journal-title":"PLoS ONE"},{"key":"3569_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1176\/jnp.15.3.340","volume":"15","author":"M Steinberg","year":"2003","unstructured":"Steinberg, M. et al. The incidence of mental and behavioral disturbances in dementia: the Cache County study. J. Neuropsychiatry Clin. Neurosci. 15, 340\u2013345 (2003).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"3569_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/gps.1316","volume":"20","author":"P Aalten","year":"2005","unstructured":"Aalten, P., de Vugt, M. E., Jaspers, N., Jolles, J. & Verhey, F. R. J. The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int. J. Geriatr. Psychiatry 20, 523\u2013530 (2005).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"3569_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/gps.1317","volume":"20","author":"P Aalten","year":"2005","unstructured":"Aalten, P., de Vugt, M. E., Jaspers, N., Jolles, J. & Verhey, F. R. J. The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables. Int. J. Geriatr. Psychiatry 20, 531\u2013536 (2005).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"3569_CR7","first-page":"976","volume":"13","author":"SH Ryu","year":"2005","unstructured":"Ryu, S. H., Katona, C., Rive, B. & Livingston, G. Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months\u2014the LASER-AD study. Am. J. Geriatr. Psychiatry 13, 976\u2013983 (2005).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"3569_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000074080","volume":"17","author":"V Senanarong","year":"2004","unstructured":"Senanarong, V. et al. Agitation in Alzheimer\u2019s disease is a manifestation of frontal lobe dysfunction. Dement. Geriatr. Cogn. Disord. 17, 14\u201320 (2004).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"3569_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000455127","volume":"17","author":"CJ Anor","year":"2017","unstructured":"Anor, C. J. et al. Neuropsychiatric symptoms in Alzheimer disease, vascular dementia, and mixed dementia. Neurodegener. Dis. 17, 127\u2013134 (2017).","journal-title":"Neurodegener. Dis."},{"key":"3569_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","volume":"173","author":"VI Reus","year":"2016","unstructured":"Reus, V. I. et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am. J. Psychiatry 173, 543\u2013546 (2016).","journal-title":"Am. J. Psychiatry"},{"key":"3569_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.644317","volume":"12","author":"C Carrarini","year":"2021","unstructured":"Carrarini, C. et al. Agitation and dementia: prevention and treatment strategies in acute and chronic conditions. Front. Neurol. 12, 644317 (2021).","journal-title":"Front. Neurol."},{"key":"3569_CR12","doi-asserted-by":"publisher","first-page":"h369","DOI":"10.1136\/bmj.h369","volume":"350","author":"HC Kales","year":"2015","unstructured":"Kales, H. C., Gitlin, L. N. & Lyketsos, C. G. Assessment and management of behavioral and psychological symptoms of dementia. BMJ 350, h369 (2015).","journal-title":"BMJ"},{"key":"3569_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1001\/jamaneurol.2024.0586","volume":"81","author":"J Cummings","year":"2024","unstructured":"Cummings, J., Lanctot, K., Grossberg, G. & Ballard, C. Progress in pharmacologic management of neuropsychiatric syndromes in neurodegenerative disorders: a review. JAMA Neurol. 81, 645\u2013653 (2024).","journal-title":"JAMA Neurol."},{"key":"3569_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","volume":"72","author":"DT Maust","year":"2015","unstructured":"Maust, D. T. et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 72, 438\u2013445 (2015).","journal-title":"JAMA Psychiatry"},{"key":"3569_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40266-022-00992-5","volume":"40","author":"M Rogowska","year":"2023","unstructured":"Rogowska, M. et al. Implications of adverse outcomes associated with antipsychotics in older patients with dementia: a 2011\u20132022 update. Drugs Aging 40, 21\u201332 (2023).","journal-title":"Drugs Aging"},{"key":"3569_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-015-0096-3","volume":"7","author":"MA Nowrangi","year":"2015","unstructured":"Nowrangi, M. A., Lyketsos, C. G. & Rosenberg, P. B. Principles and management of neuropsychiatric symptoms in Alzheimer\u2019s dementia. Alzheimers Res. Ther. 7, 12 (2015).","journal-title":"Alzheimers Res. Ther."},{"key":"3569_CR17","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","volume":"159","author":"BG Pollock","year":"2002","unstructured":"Pollock, B. G. et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am. J. Psychiatry 159, 460\u2013465 (2002).","journal-title":"Am. J. Psychiatry"},{"key":"3569_CR18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1097\/JGP.0b013e3180cc1ff5","volume":"15","author":"BG Pollock","year":"2007","unstructured":"Pollock, B. G. et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am. J. Geriatr. Psychiatry 15, 942\u2013952 (2007).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"3569_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson, A. P. et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311, 682\u2013691 (2014).","journal-title":"JAMA"},{"key":"3569_CR20","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","volume":"11","author":"LS Schneider","year":"1997","unstructured":"Schneider, L. S. et al. Validity and reliability of the Alzheimer\u2019s Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis. Assoc. Disord. 11, S22\u2013S32 (1997).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"3569_CR21","unstructured":"US Food & Drug Administration. FDA Drug Safety Communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. FDA https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related (2017)."},{"key":"3569_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1176\/appi.ajp.2015.15050648","volume":"173","author":"LS Schneider","year":"2016","unstructured":"Schneider, L. S. et al. Heterogeneity of treatment response to citalopram for patients with Alzheimer\u2019s disease with aggression or agitation: the CitAD randomized clinical trial. Am. J. Psychiatry 173, 465\u2013472 (2016).","journal-title":"Am. J. Psychiatry"},{"key":"3569_CR23","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bcp.12997","volume":"82","author":"T Ho","year":"2016","unstructured":"Ho, T. et al. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. Br. J. Clin. Pharmacol. 82, 784\u2013792 (2016).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3569_CR24","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.jagp.2015.05.006","volume":"23","author":"D Weintraub","year":"2015","unstructured":"Weintraub, D. et al. Time to response to citalopram treatment for agitation in Alzheimer disease. Am. J. Geriatr. Psychiatry 23, 1127\u20131133 (2015).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"3569_CR25","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1017\/S1041610215001106","volume":"27","author":"PB Rosenberg","year":"2015","unstructured":"Rosenberg, P. B. et al. Change in agitation in Alzheimer\u2019s disease in the placebo arm of a nine-week controlled trial. Int. Psychogeriatr. 27, 2059\u20132067 (2015).","journal-title":"Int. Psychogeriatr."},{"key":"3569_CR26","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.jalz.2019.06.4946","volume":"15","author":"S Ehrhardt","year":"2019","unstructured":"Ehrhardt, S. et al. Escitalopram for agitation in Alzheimer\u2019s disease (S-CitAD): methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimers Dement. 15, 1427\u20131436 (2019).","journal-title":"Alzheimers Dement."},{"key":"3569_CR27","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","volume":"11","author":"D Galasko","year":"1997","unstructured":"Galasko, D. et al. An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease. Alzheimer Dis. Assoc. Disord. 11, S33\u2013S39 (1997).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"3569_CR28","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1017\/S1041610210000876","volume":"22","author":"K de Medeiros","year":"2010","unstructured":"de Medeiros, K. et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int. Psychogeriatr. 22, 984\u2013994 (2010).","journal-title":"Int. Psychogeriatr."},{"key":"3569_CR29","unstructured":"Zarit, S. H., Orr, N. K. & Zarit, J. M. The Hidden Victims of Alzheimer\u2019s Disease: Families Under Stress (New York Univ. Press, 1985)."},{"key":"3569_CR30","first-page":"70","volume":"5","author":"J McConathy","year":"2003","unstructured":"McConathy, J. & Owens, M. J. Stereochemistry in drug action. Prim. Care Companion J. Clin. Psychiatry 5, 70\u201373 (2003).","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"3569_CR31","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez, C., Bogeso, K. P., Ebert, B., Reines, E. H. & Braestrup, C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 174, 163\u2013176 (2004).","DOI":"10.1007\/s00213-004-1865-z"},{"key":"3569_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0013-7006(07)91548-1","volume":"33","author":"C Jacquot","year":"2007","unstructured":"Jacquot, C., David, D. J., Gardier, A. M. & S\u00e1nchez, C. [Escitalopram and citalopram: the unexpected role of the R-enantiomer]. Encephale 33, 179\u2013187 (2007).","journal-title":"Encephale"},{"key":"3569_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1017\/S1092852900028595","volume":"7","author":"JM Gorman","year":"2002","unstructured":"Gorman, J. M., Korotzer, A. & Su, G. J. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr. 7, 40\u201344 (2002).","journal-title":"CNS Spectr."},{"key":"3569_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"3569_CR35","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1111\/jgs.13027","volume":"62","author":"RE Kennedy","year":"2014","unstructured":"Kennedy, R. E., Williams, C. P., Sawyer, P., Allman, R. M. & Crowe, M. Comparison of in-person and telephone administration of the Mini-Mental State Examination in the University of Alabama at Birmingham Study of Aging. J. Am. Geriatr. Soc. 62, 1928\u20131932 (2014).","journal-title":"J. Am. Geriatr. Soc."},{"key":"3569_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. \u2018Mini-Mental State\u2019. Practical method for grading cognitive state of patients for clinician. J. Psychiatr. Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"3569_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/S1041610214001963","volume":"27","author":"J Cummings","year":"2015","unstructured":"Cummings, J. et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int. Psychogeriatr. 27, 7\u201317 (2015).","journal-title":"Int. Psychogeriatr."},{"key":"3569_CR38","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","volume":"48","author":"JL Cummings","year":"1997","unstructured":"Cummings, J. L. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 48, S10\u2013S16 (1997).","journal-title":"Neurology"},{"key":"3569_CR39","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edn (American Psychiatric Publishing, 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"3569_CR40","unstructured":"SAS version 9.4 (SAS Institute Inc., 2013)."},{"key":"3569_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jalz.2011.01.007","volume":"8","author":"LT Drye","year":"2012","unstructured":"Drye, L. T. et al. Citalopram for agitation in Alzheimer\u2019s disease: design and methods. Alzheimers Dement. 8, 121\u2013130 (2012).","journal-title":"Alzheimers Dement."},{"key":"3569_CR42","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2021.3356","volume":"78","author":"J Mintzer","year":"2021","unstructured":"Mintzer, J. et al. Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial. JAMA Neurol. 78, 1324\u20131332 (2021).","journal-title":"JAMA Neurol."},{"key":"3569_CR43","first-page":"387","volume":"67","author":"S Mathias","year":"1986","unstructured":"Mathias, S., Nayak, U. S. L. & Isaacs, B. Balance in elderly patients\u2014the \u2018get-up and go\u2019 test. Arch. Phys. Med. Rehabil. 67, 387\u2013389 (1986).","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"3569_CR44","doi-asserted-by":"crossref","unstructured":"Davis, K. L. et al. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int. J. Geriatr. Psychiatry 12, 978\u2013988 (1997).","DOI":"10.1002\/(SICI)1099-1166(199710)12:10<978::AID-GPS659>3.0.CO;2-1"},{"key":"3569_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/jnnp.50.2.183","volume":"50","author":"HS Levin","year":"1987","unstructured":"Levin, H. S. et al. The neurobehavioral rating scale: assessment of the behavioral sequelae of head injury by the clinician. J. Neurol. Neurosurg. Psychiatry 50, 183\u2013193 (1987).","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03569-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03569-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03569-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T14:59:52Z","timestamp":1747753192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03569-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3569"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03569-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.K.R. has received research support from Brain Canada, the Brain and Behavior Research Foundation, the BrightFocus Foundation, the Canada Foundation for Innovation, the Canada Research Chair, the Canadian Institutes of Health Research (CIHR), the Centre for Aging and Brain Health Innovation, the National Institutes of Health (NIH), the Ontario Ministry of Health and Long-Term Care, the Ontario Ministry of Research and Innovation and the Weston Brain Institute. T.K.R. also received investigator-initiated study in-kind equipment support from Newronika and in-kind research online accounts from Scientific Brain Training Pro and participated in 2021 and 2022 in an advisory activity for Biogen Canada. As of 1 September 2023, T.K.R. was an ex officio member of the Board of Trustees of the Centre for Addiction and Mental Health (CAMH) in his role as Chair of the Medical Advisory Committee at CAMH in 2023 and 2024. T.K.R. is also an inventor on United States Provisional Patent 17\/396,030 that describes cell-based assays and kits for assessing serum cholinergic receptor activity. S.N.B. and D.M.S. received funding from the NIH, the American Lung Association, the State of Maryland and the US Department of Defense (DOD) (Defense Health Agency) during the period of S-CitAD. Z.I. has received research funding from the Alzheimer\u2019s Drug Discovery Foundation, the Canadian Consortium on Neurodegeneration in Aging, the CIHR, Brain Canada, the NIH and the Weston Foundation and has served as an advisor\/consultant for Eisai, Eli Lilly, Lundbeck, Novo Nordisk, Otsuka and Roche. A.M.B. is a contracting investigator with Headlands Research (Toronto Memory Program); served as a paid consultant to HealthTech Connex, Atheneum Partners; served on advisory boards and speakers\u2019 bureaus for Eisai, Avanir, Janssen, Roche, Otsuka\/Lundbeck and Boehringer Ingelheim Canada; and received research grants from the National Institute on Aging (NIA)\/NIH, the CIHR, the National Research Council, Brain Canada, Centre for Aging + Brain Health Innovation, the Ontario Shores Centre, Western University, the Lawson Health Research Institute, St Joseph\u02bcs Health Care London and the Weston Foundation. H.R.O. has received research grants from the NIH, the Alzheimer\u2019s Clinical Trials Consortium, the Alzheimer\u2019s Association, Eisai, Biogen, Optina Diagnostics, Woolsey Pharmaceuticals, the American College of Radiology and Ananda Hemp. He has received honoraria from Biogen and Optina Diagnostics. P.R.P. received research support from the Office of Research Development, the US Department of Veterans Affairs, the Alzheimer\u2019s Association and the NIH. P.B.R. has received research grants from the NIA, the Alzheimer\u2019s Clinical Trials Consortium, the Richman Family Precision Medicine Center of Excellence in Alzheimer\u2019s Disease, Eisai, Functional Neuromodulation Ltd and Eli Lilly; and honoraria from Eli Lilly, Guidepoint, GLG, Leerink, Cerevel, Cerevance, BioXcel, Sunovion, Acadia, Medalink, Novo Nordisk, Noble Insights, TwoLabs, Otsuka, Lundbeck, Acadia, MEDACorp, ExpertConnect, HMP Global, Sinaptica, Synaptogenix and Neurology Week. P.B.R. has received grant support from the NIA (AGRO1054771 (CRD), AGRO1050515 (dronabinol) and AGRO1046543 (ADMET II)). L.S.S. reports, within a 36-month timeframe, grants from the NIH (R01 AG054434 (Delivery of essential fatty acids to the brain in Alzheimer\u2019s disease), P30 AG066530 (USC ADRC), R01 AG062687, R01 AG051346, R01 AG055444, P01 AG02350, R01 AG053267 (DIAN-TU), R01 AG074983 (A\u03b2 and tau vaccines) and R01 AG063826 (State of California CADC 15-10291)); grants and personal fees from Eli Lilly\/Avid; grants and personal fees from Roche\/Genentech; grants\/contracts from Eisai, Biogen and Biohaven; grants from Washington University in St Louis\/NIA DIAN-TU; grants from UC San Diego ADCS; personal fees from Neurim (Israel), Cognition Therapeutics, Corium, Immunobrain Checkpoint Ltd (Israel), Alpha Cognition, BioVie, Lexeo, Lighthouse, AC Immune (Switzerland), Athira, GW Research (UK, Jazz, USA), Merck, Otsuka (USA), Pharmatrophix, Linus Health, Lundbeck, Novo Nordisk, Muna (Denmark), ONO Ltd and Vivli.org, all outside the submitted work; and support from the Della Martin Foundation endowment. A.P.P. reports personal fees from Acadia Pharmaceuticals, Athira, Biogen, Bristol Myers Squibb, Cognitive Research Corporation, Eisai, IQVIA, Lundbeck, Novartis, ONO Pharmaceuticals, WCG, WebMD and Xenon and grants to his institution from Alector, Athira, Biogen, Cassava, Eisai, Eli Lilly, Genentech\/Roche, Vaccinex, the NIA, the National Institute of Mental Health and the DOD. He is a member of the scientific advisory boards of Alzheon, Athira and Cognition Therapeutics. C.G.L. has received research funding from the NIH, the Alzheimer\u02bcs Association, NFL Benefits, Functional Neuromodulation Ltd, the BrightFocus Foundation and private donors. He has served as a paid consultant or advisor for AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Eli Lilly, Pfizer, Genentech, Elan, the NFL Players Association, the NFL Benefits Office, Zinfandel, Bristol Myers Squibb, AbbVie, Janssen, Orion, Servier, Astellas, SVB Leerink, Roche, Avanir, Karuna, Maplight, Axsome, GIA, GW Research Ltd, Merck, EXCIVA GmbH, Otsuka, Intra-Cellular Therapies and Medesis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}